文献速递心力衰竭与心肌病冠心病

经皮短期主动机械支持装置在心源性休克中的系统评价与协作荟萃分析

Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials.
PubMed 文献 · Eur Heart J · 2017-01-01

该协作荟萃分析纳入4项随机试验共148例心源性休克患者,比较经皮主动机械循环支持(MCS)与对照(均为IABP)的疗效与安全性。结果显示MCS未降低30天死亡率,但显著升高平均动脉压并降低动脉乳酸,同时出血风险显著增加。结论不支持在急性心肌梗死合并心源性休克患者中无选择地使用主动MCS。

要点

  • 经皮主动MCS与IABP相比未改善30天死亡率(RR 1.01)。
  • MCS显著升高平均动脉压并降低动脉乳酸,但出血风险增加。
  • 不推荐在AMI合并心源性休克患者中无选择地使用主动MCS。

核心结论

  • 协作荟萃分析结果不支持在急性心肌梗死合并心源性休克患者中无选择地使用主动机械循环支持装置。

研究设计与样本

  • 系统检索医学文献数据库,纳入比较经皮主动机械循环支持与对照的随机试验,共4项试验、148例患者(MCS组77例,对照组71例),对照组均使用主动脉内球囊反搏(IABP)。

主要发现

  • 30天死亡率无差异(RR 1.01,95%CI 0.70-1.44,P=0.98,I2=0%)。
  • 主动MCS显著升高平均动脉压(MD 11.85 mmHg,95%CI 3.39-20.31,P=0.02,I2=32.7%)并降低动脉乳酸(MD -1.36 mmol/L,95%CI -2.52至-0.19,P=0.02,I2=0%)。
  • 心脏指数(MD 0.32,95%CI -0.24-0.87,P=0.14)和肺毛细血管楔压(MD -5.59,95%CI -15.59-4.40,P=0.14)无显著差异。
  • 下肢缺血发生率无显著差异(RR 2.64,95%CI 0.83-8.39,P=0.10,I2=0%),但出血发生率显著增加(RR 2.50,95%CI 1.55-4.04,P<0.001,I2=0%)。

临床怎么用

  • 在急性心肌梗死合并心源性休克患者中,不应无选择地常规使用经皮主动机械循环支持装置。
  • 使用主动MCS需权衡血流动力学改善与出血风险增加。

局限性

  • 仅纳入4项随机试验共148例患者,样本量小。
  • 对照组均为IABP,未与其他支持方式比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Evidence on the impact on clinical outcome of active mechanical circulatory support (MCS) devices in cardiogenic shock (CS) is scarce. This collaborative meta-analysis of randomized trials thus aims to investigate the efficacy and safety of percutanzeous active MCS vs. control in CS. METHODS AND RESULTS: Randomized trials comparing percutaneous active MCS to control in patients with CS were identified through searches of medical literature databases. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated to analyse the primary endpoint of 30-day mortality and device-related complications including bleeding and leg ischaemia. Mean differences (MD) were calculated for mean arterial pressure (MAP), cardiac index (CI), pulmonary capillary wedge pressure (PCWP), and arterial lactate. Four trials randomizing 148 patients to either TandemHeart™ or Impella® MCS (n = 77) vs. control (n = 71) were identified. In all four trials intra-aortic balloon pumping (IABP) served as control. There was no difference in 30-day mortality (RR 1.01, 95% CI 0.70 to 1.44, P = 0.98, I2 = 0%) for active MCS compared with control. Active MCS significantly increased MAP (MD 11.85 mmHg, 95% CI 3.39 to 20.31, P = 0.02, I2 = 32.7%) and decreased arterial lactate (MD - 1.36 mmol/L, 95% CI - 2.52 to - 0.19, I2 = 0%, P = 0.02) at comparable CI (MD 0.32, 95% CI - 0.24 to 0.87, P = 0.14, I2 = 44.1%) and PCWP (MD - 5.59, 95% -15.59 to 4.40, P = 0.14, I2 = 81.1%). No significant difference was observed in the incidence of leg ischaemia (RR 2.64, 95% CI 0.83 to 8.39, P = 0.10, I2 = 0%), whereas the rate of bleeding was significantly increased in MCS compared to IABP (RR 2.50, 95% CI 1.55 to 4.04, P < 0.001, I2 = 0%). CONCLUSION: Results of this collaborative meta-analysis do not support the unselected use of active MCS in patients with CS complicating AMI.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J. 2017. PMID: 29020341. doi:10.1093/eurheartj/ehx363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。